InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,475.09
(
0.27%
)
US TECH 100
19,173.20
(
-0.54%
)
Dow Jones
39,169.52
(
0.00%
)
Brent Oil
87.08
(
0.63%
)
Bitcoin
62,676.15
(
-0.28%
)
Post# of 252455
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119964
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 177549

Tuesday, 05/06/2014 2:36:05 PM

Tuesday, May 06, 2014 2:36:05 PM

Post# of 252455
AZN talks up pipeline (while continuing to reject PFE’s sweetened ofer):

http://online.wsj.com/news/articles/SB10001424052702304831304579545330367321414

New sales estimates AstraZeneca gave Tuesday for its pipeline drugs include up to $6.5 billion for its biggest hope: new cancer treatment MEDI4736, compared with analyst estimates of $2 billion to $7 billion cited by the company.

AstraZeneca also set out new revenue targets for its five growth areas. Annual revenue estimates for 2023 now include $3.5 billion from its blood-thinning pill Brilinta, $8 billion from its portfolio of diabetes drugs and $8 billion from respiratory drugs. The company said it expects mid-to-high-single-digit percentage revenue growth in emerging markets and low-single-digit revenue growth in Japan.

The $3.5B target for Brilinta will be tough to meet, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up